Ocular Surface Disease Clinical Trial
Official title:
Efficacy and Safety of LK Scleral Lens for Patients With Intractable Ocular Surface Diseases: A Prospective, Multicenter, Open-Label, Single-Arm Clinical Trial
Scleral lenses have emerged as an efficacious treatment option for various types of intractable ocular surface diseases with many advantageous results. The purpose of this study was to report the efficacy and safety of the LK scleral lenses and determine their suitability in Asian patients with intractable ocular surface diseases. Subjects with intractable ocular surface diseases are enrolled to fit LK scleral lenses for 12 weeks for a prospective study. Evaluations are performed at 1, 4, 8 and 12 weeks. General patient demographics and medical history, visual acuities, thorough ophthalmic evaluation, ocular surface disease index and National Eye Institute 25-Item Visual Function Questionnaire are collected for each patient.
To date, there are several commercially manufactured scleral lenses of different designs and
sizes, all of which have been proven to be clinically beneficial in a wide spectrum of
diseases. Especially in the management of intractable ocular surface diseases, scleral lenses
with large diameters are commonly used so that the lens entirely rests on the sclera with
sufficient tear reservoir. PROSE devices (Boston Foundation for Sight, Needham, MA), one of
the first and representative scleral lenses shown to have long-term clinical benefits for
complex corneal diseases, have large diameters of 17.5 to 23.0 mm. However, in Republic of
Korea, only scleral lenses with small diameters are currently available. SoClearⓇ and OnefitⓇ
scleral lenses, two of the most commonly used scleral lenses in Republic of Korea, possess
diameters ranging from 14.1 to 15.5 mm and 13.3 to 15.0 mm, respectively, and are not
actually fully scleral but more of a corneoscleral type lenses. Furthermore, Asians have
smaller palpebral fissures with tighter eyelids than the Western population, which may
restrict patients' tolerability of wearing a large scleral lens and limit its clinical
benefits. Therefore, a more suitable scleral lens for Asians with larger diameter is
required.
Accordingly, this study investigates the efficacy and safety of the LK scleral lens (Lucid
Korea LTD, Seoul, Republic of Korea), which has been newly manufactured to have larger
diameters than currently available commercial lenses, and determines their suitability in
Asian patients with intractable ocular surface diseases.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04067973 -
Impact of Prematurity on the Optic Nerve
|
||
Completed |
NCT04828057 -
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
|
||
Not yet recruiting |
NCT06375343 -
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
|
Phase 1 | |
Completed |
NCT00346450 -
Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation
|
Phase 3 | |
Completed |
NCT04351100 -
Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients
|
||
Completed |
NCT03659955 -
Autologous Blood Treatment for Ocular Surface Disease
|
N/A | |
Completed |
NCT04536129 -
Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure
|
N/A | |
Completed |
NCT01254370 -
Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease
|
Phase 2 | |
Completed |
NCT00554411 -
Assessing Ocular Surface Changes After Changing Glaucoma Medications
|
N/A | |
Completed |
NCT03769454 -
A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers
|
Phase 1 | |
Recruiting |
NCT06256770 -
Evaluation of the Safety and Efficacy of Rigid Breathable Scleral Contact Lenses for the Correction of Ametropia
|
||
Completed |
NCT04673604 -
From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy
|
N/A | |
Not yet recruiting |
NCT06370585 -
Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF
|
Phase 1 | |
Withdrawn |
NCT04735510 -
Novel Use of Restasis and PROSE Devices
|
Phase 3 | |
Suspended |
NCT00348114 -
Transplantation of Cultivated Limbal Epithelium on Amniotic Membrane for Limbal Stem Cell Deficiency
|
Phase 2 | |
Recruiting |
NCT04010422 -
Ocular Function in Autism Spectrum Disorder
|
||
Completed |
NCT05528016 -
Short and Long-term Results of Skin Versus Skin Plus Orbicularis Resection Blepharoplasty
|
N/A | |
Completed |
NCT04452279 -
Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification
|
N/A | |
Recruiting |
NCT06298890 -
The Pattern of Dry Eye Disease After Cataract Surgery
|
||
Completed |
NCT02802137 -
24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy
|
Phase 4 |